{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:24:17Z","timestamp":1766690657380,"version":"3.41.2"},"reference-count":90,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323899413"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007427","name":"MPN Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K08HL138142"],"award-info":[{"award-number":["1K08HL138142"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2021.08.001","type":"book-chapter","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T23:10:44Z","timestamp":1644448244000},"page":"1-24","source":"Crossref","is-referenced-by-count":5,"title":["The roles of sex and genetics in the MPN"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2021.08.001_bb0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183620","article-title":"Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development","volume":"12","author":"Andersen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0020","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-018-0231-9","article-title":"Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32","volume":"32","author":"Babushok","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0035","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","article-title":"Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"97","author":"Boddu","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0050","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.hoc.2019.11.006","article-title":"The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic","volume":"34","author":"Bolton","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0060","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.3390\/cancers13133246","article-title":"Germline ERBB2\/HER2 coding variants are associated with increased risk of myeloproliferative neoplasms","volume":"13","author":"Braunstein","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0070","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature03479","article-title":"X-inactivation profile reveals extensive variability in X-linked gene expression in females","volume":"434","author":"Carrel","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0080","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0090","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41375-020-0935-5","article-title":"Male predominance in AML is associated with specific preleukemic mutations","volume":"35","author":"De-Morgan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0095","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2016.1246726","article-title":"Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)","volume":"58","author":"DeZern","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ng.3726","article-title":"Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias","volume":"49","author":"Dunford","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10654-011-9647-5","article-title":"Enigmatic sex disparities in cancer incidence","volume":"27","author":"Edgren","year":"2012","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0110","first-page":"1300","article-title":"How obesity affects the neutrophil\/lymphocyte and platelet\/lymphocyte ratio, systemic immune-inflammatory index and platelet indices: a retrospective study","volume":"20","author":"Furuncuoglu","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-020-20565-7","article-title":"Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis","volume":"12","author":"Gao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0120","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bbadis.2014.05.018","article-title":"The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases","volume":"1842","author":"Garbers","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0125","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0130","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0140","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2015-09-668673","article-title":"Germline RBBP6 mutations in familial myeloproliferative neoplasms","volume":"127","author":"Harutyunyan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0150","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","article-title":"Sex disparities matter in cancer development and therapy","volume":"21","author":"Haupt","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020010163","article-title":"CHIP & HIPs: clonal hematopoiesis is common in hip arthroplasty patients and associates with autoimmune disease","author":"Hecker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0165","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0170","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/03630269.2012.724040","article-title":"A new ATRX mutation in a patient with acquired \u03b1-thalassemia myelodysplastic syndrome","volume":"36","author":"Herbaux","year":"2012","journal-title":"Hemoglobin"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.24073","article-title":"Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis","volume":"90","author":"Herbaux","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0180","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0185","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0195","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020005792","article-title":"Germline genetic factors influence the outcome of interferon-\u03b1 therapy in polycythemia vera","volume":"137","author":"J\u00e4ger","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0200","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0210","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjh.16321","article-title":"Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2.3 million people","volume":"189","author":"Jayasuriya","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0225","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0230","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjh.17534","article-title":"Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"193","author":"Karantanos","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0235","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clml.2016.02.036","article-title":"Outcome disparities in Caucasian and non-Caucasian patients with myeloproliferative neoplasms","volume":"16","author":"Khan","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0240","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0245","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0250","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0255","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0260","article-title":"Germline POT1 variants can predispose to myeloid and lymphoid neoplasms","author":"Lim","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25673","article-title":"Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes","volume":"95","author":"Madan","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0270","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0275","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0280","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0285","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0290","article-title":"Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence","volume":"3","author":"Nazha","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0295","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0305","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0310","doi-asserted-by":"crossref","first-page":"100280","DOI":"10.1016\/j.eclinm.2020.100280","article-title":"Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: a Mendelian randomization study","volume":"21","author":"Pedersen","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0315","article-title":"Germline ATG2B\/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms","author":"Pegliasco","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0320","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0330","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.25486","article-title":"DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease","volume":"94","author":"Quesada","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0335","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2017.07.013","article-title":"Sex differences in cancer risk and survival: a Swedish cohort study","volume":"84","author":"Radkiewicz","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0340","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","article-title":"Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis","volume":"5","author":"Renosi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0345","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0350","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0355","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3380","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0360","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.2019003264","article-title":"Cancer spectrum and outcomes in the mendelian short telomere syndromes","volume":"135","author":"Schratz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0365","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.annepidem.2005.06.052","article-title":"Platelet counts differ by sex, ethnicity, and age in the United States","volume":"16","author":"Segal","year":"2006","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0370","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0375","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0380","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0385","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients","volume":"39","author":"Stein","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0395","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0400","doi-asserted-by":"crossref","first-page":"424","DOI":"10.6004\/jnccn.2015.0058","article-title":"Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms","volume":"13","author":"Stein","year":"2015","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0405","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.2019001362","article-title":"Analysis of 153115 patients with hematological malignancies refines the spectrum of familial risk","volume":"134","author":"Sud","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0410","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0415","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms","volume":"28","author":"Van Egeren","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0425","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ng.349","article-title":"Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer","volume":"41","author":"van Haaften","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0435","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.7150\/jca.28220","article-title":"Gender disparity in the survival of patients with primary myelodysplastic syndrome","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0440","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.2019002039","article-title":"Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice","volume":"134","author":"Xavier-Ferrucio","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0445","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1073\/pnas.1407688111","article-title":"Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers","volume":"111","author":"Xu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0450","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ajh.25592","article-title":"The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia","volume":"94","author":"Zheng","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.08.001_bb0455","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2013 Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821001040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821001040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:21:08Z","timestamp":1753341668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323899413"],"references-count":90,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.08.001","relation":{},"ISSN":["1937-6448"],"issn-type":[{"type":"print","value":"1937-6448"}],"subject":[],"published":{"date-parts":[[2022]]}}}